



Friday, Januar 24, 2025 – Urothelial Carcinoma

13:00 – 13:10	Welcome Session Welcome Words
13:10 – 15:20	Pathology, genetics and NMIBC Session content: <i>Urothelial pathology: variants, biomarker and consequences; Genetics; NMIBC – new approaches</i>
	<i>Coffee Break 15:20 – 15:50</i>
15:50 – 18:10	Advanced disease Session content: <i>MIBC: neoadjuvant – new kids on the block, 1st- and 2nd-line therapy, Treatment of older patients: Do we need geriatric assessment</i>
	<i>Welcome Reception at the Venue 18:10 – 19:30</i>



Kidney – Saturday, January 25, 2025

	<i>Welcome Coffee 08:30 - 09:00</i>
09:00 - 10:00	State of the Art first-Line treatment of mRCC in clear cell and non-clear cell histologies, drivers for treatment decisions <i>including cases</i>
10:00 - 10:45	Second-Line treatment, results of pivotal trials, is there a role for treatment beyond progression? <i>including cases</i>
10:45 - 11:45	Second-Line treatment, results of pivotal trials, is there a role for treatment beyond progression? <i>including cases</i>
	<i>Break 11:45 - 12:15</i>
12:15 - 13:00	What is the role of immune-check-point inhibitors in the adjuvant setting of RCC, results and analysis of pivotal trials
13:00 - 13:20	A physician who becomes a patient.
13:20 - 13:30	Closing remarks